30 results on '"Capetti AF"'
Search Results
2. Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
- Author
-
Landonio, S, Meraviglia, P, Capetti, Af, Di Biagio, A, Lo Caputo, S, Sterrantino, G, Ammassari, A, Menzaghi, B, Franzetti, M, De Socio, G, Pellicanò, G, Mazzotta, E, Zucchi, P, and Rizzardini, G
- Subjects
HIV patients -- Care and treatment ,Raltegravir -- Dosage and administration ,HIV infection -- Risk factors -- Prevention ,Health - Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Background Raltegravir is the first integrase inhibitor to get into the clinic and the MK‐0518 Expanded Access Program (EAP) started in Italy in 2007, so that most patients now have [...]
- Published
- 2010
- Full Text
- View/download PDF
3. Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
- Author
-
Rusconi, S, primary, Vitiello, P, additional, Adorni, F, additional, Colella, E, additional, Focà, E, additional, Capetti, AF, additional, Meraviglia, P, additional, Abeli, C, additional, Bonora, S, additional, D'Annunzio, M, additional, Di Biagio, A, additional, Di Pietro, A, additional, Butini, L, additional, Orofino, G, additional, Farina, S, additional, d'Ettorre, G, additional, Francisci, D, additional, Soria, A, additional, Buonomini, AR, additional, Tommasi, C, additional, Trotta, MP, additional, Capasso, M, additional, Merlini, E, additional, and Marchetti, GC, additional
- Published
- 2010
- Full Text
- View/download PDF
4. Unexpected CD4 decay, hidden adherence gaps, resilience, and the need for long-acting therapy in a single HIV outpatients' cohort.
- Author
-
Mariani C, Borgonovo F, Gerbi M, Rizzardini G, and Capetti AF
- Subjects
- Humans, CD4 Lymphocyte Count, Male, Female, Middle Aged, Adult, Cohort Studies, COVID-19, SARS-CoV-2, Outpatients psychology, HIV Infections drug therapy, HIV Infections psychology, Medication Adherence psychology, Medication Adherence statistics & numerical data, Anti-HIV Agents therapeutic use, Viral Load
- Abstract
This single-centre, single-cohort study examines hidden non-adherence to antiretroviral therapy in a setting of persistent optimal viral suppression but concordant absolute and percent CD4 decay by >10% from the previous test. After the finding of important drug holidays in two virologically suppressed patients, between January 2021 and January 2022 all PLWH who fulfilled CD4 decay criteria were asked for how long therapy was interrupted, how many days before re-testing CD4 and HIV RNA was it resumed and the reason for interruption. Of 668 HIV-infected subjects, 61 fulfilled the pre-specified criteria for significant CD4 decay and 15 (2.25% of the total, 25% of the CD4 decay group) admitted long-lasting treatment interruptions, compensated by treatment resumption before the subsequent testing. Eleven treatment interruptions exceeded 28 days, and none was shorter than 15 days. CD4 recovery was worse at 6 months in non-adherent subjects (-0.5 vs + 16/mmc, p < 0.0001) and in non adherence vs immune decay time-related with COVID-19 (0 vs + 22/mmc, p < 0.0001). Reasons for interrupting treatment were travel, psychological, poverty-related, addiction and sentimental sphere problems. Long-acting regimens, with stringent control of precision in timely administration, may protect PLWH from damaging their health status and possibly transmit HIV.
- Published
- 2024
- Full Text
- View/download PDF
5. Analysis and clinical determinants of post-COVID-19 syndrome in the Lombardy region: evidence from a longitudinal cohort study.
- Author
-
Borgonovo F, Lovaglio PG, Mariani C, Berta P, Cossu MV, Rizzardini G, Vittadini G, and Capetti AF
- Subjects
- Humans, Male, Female, Post-Acute COVID-19 Syndrome, Longitudinal Studies, Prospective Studies, Quality of Life, Cohort Studies, COVID-19 epidemiology
- Abstract
Objective: To define macro symptoms of long COVID and to identify predictive factors, with the aim of preventing the development of the long COVID syndrome., Design: A single-centre longitudinal prospective cohort study conducted from May 2020 to October 2022., Setting: The study was conducted at Luigi Sacco University Hospital in Milan (Italy). In May 2020, we activated the ARCOVID (Ambulatorio Rivalutazione COVID) outpatient service for the follow-up of long COVID., Participants: Hospitalised and non-hospitalised patients previously affected by COVID-19 were either referred by specialists or general practitioners or self-referred., Intervention: During the first visit, a set of questions investigated the presence and the duration of 11 symptoms (palpitations, amnesia, headache, anxiety/panic, insomnia, loss of smell, loss of taste, dyspnoea, asthenia, myalgia and telogen effluvium). The follow-up has continued until the present time, by sending email questionnaires every 3 months to monitor symptoms and health-related quality of life., Primary and Secondary Outcome Measures: Measurement of synthetic scores (aggregation of symptoms based on occurrence and duration) that may reveal the presence of long COVID in different clinical macro symptoms. To this end, a mixed supervised and empirical strategy was adopted. Moreover, we aimed to identify predictive factors for post-COVID-19 macro symptoms., Results: In the first and second waves of COVID-19, 575 and 793 patients (respectively) were enrolled. Three different post-COVID-19 macro symptoms (neurological, sensorial and physical) were identified. We found significant associations between post-COVID-19 symptoms and (1) the patients' comorbidities, and (2) the medications used during the COVID-19 acute phase. ACE inhibitors (OR=2.039, 95% CI: 1.095 to 3.892), inhaled steroids (OR=4.08, 95% CI: 1.17 to 19.19) and COVID therapies were associated with increased incidence of the neurological macro symptoms. Age (OR=1.02, 95% CI: 1.01 to 1.04), COVID-19 severity (OR=0.42, 95% CI: 0.21 to 0.82), number of comorbidities (OR=1.22, 95% CI: 1.01 to 1.5), metabolic (OR=2.52, 95% CI: 1.25 to 5.27), pulmonary (OR=1.87, 95% CI: 1.10 to 3.32) and autoimmune diseases (OR=4.57, 95% CI: 1.57 to 19.41) increased the risk of the physical macro symptoms., Conclusions: Being male was the unique protective factor in both waves. Other factors reflected different medical behaviours and the impact of comorbidities. Evidence of the effect of therapies adds valuable information that may drive future medical choices., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
6. Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects.
- Author
-
Borgonovo F, Stangalini CA, Tinelli C, Mariani C, Mileto D, Cossu MV, Abbati L, Bilardo L, Gagliardi G, Cutrera M, Pellicciotta M, Armiento L, Dedivitiis G, Capetti AF, and Rizzardini G
- Subjects
- Aged, Antibodies, Viral, BNT162 Vaccine, Humans, Immunoglobulin G, SARS-CoV-2, Vaccination, COVID-19 prevention & control
- Abstract
Vaccination toward SARS-CoV-2 reduced mortality and 'boosters' are being implemented. We offer scientific contribution about IgG production in the COVID-19 experienced population. From January 2021 to March 2021, 183 residents and staff from the Elderly Nursing Home "San Giuseppe Moscati" who had received two doses of the BNT162b2 vaccine were enrolled. The antibody response was assessed by the DiaSorin LIAISON-CLIA S1/S2® IgG solution. Cutoff levels for response (>39 BAU/mL) and neutralizing activity (>208 BAU/mL) were derived from DiaSorin official data. Serology was assessed before and after the first vaccination, and 2 weeks and 6 months after the second vaccination. Anti-S IgG in COVID-19 experienced, baseline IgG producers spiked after the first vaccination to median 5044 BAU/mL and decayed at 6 months to 2467.4 BAU/mL. Anti-S IgG in COVID-19 experienced, baseline IgG non-producers spiked after the second vaccination to median 1701.7 BAU/mL and decayed at 6 months to 904.8 BAU/mL. Anti-S IgG in COVID-19 naïve subjects spiked after the second vaccination to median 546 BAU/mL and decayed at 6 months to 319.8 BAU/mL. The differences between sequential timepoint levels in each group were statistically significant (p < .0001). Serology analysis revealed different kinetics between COVID-19 experienced subjects depending on baseline response, possibly predicting different IgG persistence in blood.
- Published
- 2022
- Full Text
- View/download PDF
7. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
- Author
-
Rusconi S, Santoro MM, Capetti AF, Gianotti N, and Zazzi M
- Subjects
- Diketopiperazines, Humans, Pyridones therapeutic use, Rilpivirine therapeutic use, Anti-HIV Agents adverse effects, HIV Infections drug therapy, HIV-1
- Abstract
HIV infection is currently managed as a chronic disease because of improvements in antiretroviral therapy (ART). Switching to a new regimen is a natural event during long-term therapy to avoid problems related to toxicity, adherence, failure, and potential selection of drug resistance. The development of co-formulations of multiple agents in one pill, and novel drug classes and drugs with a high genetic barrier to resistance have been important in this context. The approval of the long-acting, once-monthly or bimonthly injectable combination of the second-generation strand transfer integrase inhibitor (InSTI), cabotegravir (CAB) together with the non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (RPV) represents the most recent achievement in the search for potent and convenient ART. Several pivotal trials (such as LATTE-2, ATLAS, FLAIR, and ATLAS-2M) showed the high efficacy and safety of this long-acting formulation used as an induction-maintenance strategy. Few confirmed virological failures (CVF) have been observed. The combination of at least two of the following baseline factors, HIV-1 subtype A6/A1, a body mass index (BMI) ≥30 kg/m
2 , and RPV resistance-associated mutations, was associated with an increased risk of CVF at week 48. The data indicate that this long-acting therapeutic strategy is attractive and potent; therefore, defining the most appropriate patient for this treatment and how to handle practical issues is warranted., Competing Interests: Declaration of Competing Interest Stefano Rusconi reports honoraria for presentations and scientific advice for Merck, Sharp & Dohme, Theratechnologies, GSK, Janssen Cilag, ViiV Healthcare, and Gilead Sciences and research grants for his institution from Janssen Cilag, ViiV Healthcare, and Gilead Sciences; Maria Mercedes Santoro has received funds for attending symposia, speaking and organizing educational activities from ViiV Healthcare, Janssen-Cilag and Theratechnologies; Amedeo F. Capetti has received personal fees for advisory boards and speaker's bureau from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, and ViiV Healthcare; Nicola Gianotti has been an advisor for Gilead Sciences, Janssen-Cilag, ViiV Healthcare and Merck Sharp & Dohme and has received speakers’ honoraria from Gilead Sciences, ViiV Healthcare, Janssen-Cilag, Bristol-Myers Squibb and Merck Sharp & Dohme; Maurizio Zazzi has received grants for research and educational activities from Gilead Sciences, Merck Sharp and Dohme, Theratechnologies and ViiV Healthcare; and he has received personal fees for advisory boards and speaker's bureau from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, Theratechnologies, and ViiV Healthcare., (Copyright © 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
8. Persistence of Long-COVID symptoms in a heterogenous prospective cohort.
- Author
-
Mariani C, Borgonovo F, Capetti AF, Oreni L, Cossu MV, Pellicciotta M, Armiento L, Bocchio S, Dedivitiis G, Lupo A, Galli M, and Rizzardini G
- Subjects
- Cohort Studies, Humans, Prospective Studies, SARS-CoV-2, Post-Acute COVID-19 Syndrome, COVID-19 complications
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2022
- Full Text
- View/download PDF
9. Brief Report: Impact of the COVID-19 Pandemic on Virological Suppression in People Living With HIV Attending a Large Italian HIV Clinic.
- Author
-
Giacomelli A, Bonazzetti C, Conti F, Pezzati L, Oreni L, Micheli V, Mancon A, Vimercati S, Albrecht M, Passerini M, Cossu MV, Capetti AF, Meraviglia P, Antinori S, Rizzardini G, Galli M, and Ridolfo AL
- Subjects
- Ambulatory Care Facilities, Anti-HIV Agents administration & dosage, Delivery of Health Care methods, HIV Infections drug therapy, HIV-1, Humans, Italy epidemiology, RNA, Viral blood, SARS-CoV-2, Viral Load drug effects, Anti-HIV Agents therapeutic use, COVID-19 complications, COVID-19 epidemiology, HIV Infections complications, HIV Infections epidemiology
- Abstract
Background: We assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on HIV suppression rates in people living with HIV (PLWH) attending a large Italian HIV clinic., Setting: The HIV outpatient clinic of the Infectious Diseases Department of Luigi Sacco Hospital, Milan, Italy, which serves more than 5000 PLWH per year., Methods: A before and after quasi-experimental study design was used to make a retrospective assessment of the monthly trend of HIV-RNA determinations of ≥50 among the PLWH attending our clinic, with "before" being the period from January 1, 2016 to February 20, 2020, and "after" being the period from February 21, 2020 to December 31, 2020 (the COVID-19 period). Interrupted time series analysis was used to evaluate any changes in the trend., Results: During the study period, 70,349 HIV-RNA viral load determinations were made, and the percentage of HIV-RNA viral load determinations of <50 copies/mL increased from 88.4% in 2016 to 93.2% in 2020 (P < 0.0001). There was a significant monthly trend toward a decrease in the number of HIV-RNA determinations of ≥50 copies/mL before the pandemic (β -0.084; standard error 0.015; P < 0.001), and this did not significantly change after it started (β -0.039, standard error 0.161; P = 0.811)., Conclusions: A high prevalence of viral suppression was maintained among the PLWH referring to our clinic, despite the structural barriers raised by the COVID-19 pandemic. The use of simplified methods of delivering care (such as teleconsultations and multiple antiretroviral treatment prescriptions) may have contributed to preserving this continuum., Competing Interests: The authors have no funding or conflicts of interest to disclose., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.
- Author
-
Capetti AF, Stangalini CA, Borgonovo F, Mileto D, Oreni L, Dedivitiis G, Lupo A, Cossu MV, Bilardo L, Giacomelli A, Galli M, and Rizzardini G
- Subjects
- BNT162 Vaccine, Humans, Immunoglobulin G, RNA, Messenger, SARS-CoV-2, COVID-19, COVID-19 Vaccines
- Published
- 2021
- Full Text
- View/download PDF
11. One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG.
- Author
-
Capetti AF, Borgonovo F, Mileto D, Gagliardi G, Mariani C, Lupo A, Dedivitiis G, Meraviglia P, Pellicciotta M, Armiento L, Cossu MV, and Rizzardini G
- Subjects
- Antibodies, Viral, Humans, Immunoglobulin G, Preliminary Data, Prospective Studies, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2
- Abstract
Data are presented of 368/503 post-COVID-19 outpatients followed within the AntiCROWN Cohort who have a one-year control and a baseline assessment of anti-S1/S2 antibodies, detected with the The LIAISON® SARS-CoV-2 S1/S2 IgG solution by DiaSorin. Loss of response occurred in 4 subjects having a baseline level below 50 AU/mL., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
12. Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study.
- Author
-
Borgonovo F, Passerini M, Piscaglia M, Morena V, Giacomelli A, Oreni L, Dedivitiis G, Lupo A, Falvella S, Cossu MV, and Capetti AF
- Subjects
- Humans, Prospective Studies, Reinfection, Spike Glycoprotein, Coronavirus, COVID-19, SARS-CoV-2
- Published
- 2021
- Full Text
- View/download PDF
13. Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal carriers.
- Author
-
Capetti AF, Borgonovo F, Morena V, Lupo A, Cossu MV, Passerini M, Dedivitiis G, and Rizzardini G
- Subjects
- Adult, Antiviral Agents therapeutic use, Carrier State virology, Female, Humans, Male, Middle Aged, Nasopharynx virology, SARS-CoV-2 isolation & purification, Treatment Outcome, Virus Shedding drug effects, Carrier State drug therapy, Hydrogen Peroxide therapeutic use, Oxidants therapeutic use, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
- Abstract
Asymptomatic and convalescent coronavirus disease 2019 (COVID-19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15-20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS-CoV-2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared "cured" (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects., (© 2020 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
14. Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort.
- Author
-
Ciccullo A, Baldin G, Borghi V, Sterrantino G, Madeddu G, Latini A, d'Ettorre G, Lanari A, Mazzitelli M, Colafigli M, Capetti AF, Oreni L, Lagi F, Rusconi S, and Di Giambenedetto S
- Subjects
- Heterocyclic Compounds, 3-Ring adverse effects, Humans, Italy, Male, Middle Aged, Oxazines therapeutic use, Piperazines therapeutic use, Raltegravir Potassium adverse effects, HIV Infections drug therapy, HIV Integrase Inhibitors adverse effects
- Abstract
International guidelines recommend the use of integrase strand transfer inhibitor (INI)-based regimens as first-line antiretroviral (ARV) in both naive and experienced HIV-infected patients. We analyzed a multicenter cohort of HIV-infected patients, both naive and experienced, starting an ARV, including an INI. Chi-square test and nonparametric tests were used to assess differences in categorical and continuous variables, respectively. Kaplan-Meier survival analysis was performed to estimate the probability of maintaining the study drug and Cox-regression analysis to evaluate predictors of discontinuation. We enrolled 4,343 patients: 3,143 (72.4%) were males, with a median age of 49 years (interquartile range 41-55). Naive patients were 733 (16.9%), of whom 168 (22.9%) were AIDS presenters. Overall, 2,282 patients (52.5%) started dolutegravir (DTG), 1,426 (32.8%) raltegravir (RAL), and 635 (14.7%) elvitegravir (EVG). During 10,032 patient years of follow-up (PYFU), we observed 1,278 discontinuations (13 per 100 PYFU); 448 of them (35%) due to simplification and 355 (28%) to toxicities (98 for central nervous system toxicity). Reasons of discontinuation were different between INIs. Estimated probability of maintaining DTG at 3 and 4 years were 81.5% [95% confidence interval (CI): 80.5-82.5] and 76.3% (95% CI: 73.9-78.7), respectively; RAL 61.6% (95% CI: 60.2-63.0) and 54.1% (95% CI: 52.7-55.5); EVG 71.6% (95% CI: 69.2-74.0) and 68.3% (95% CI: 65.3-71.3) ( p < .001). At a multivariable analysis, being on a RAL-based ARV [vs. DTG, adjusted hazard ratio (aHR) 2.9, 95% CI: 2.3-3.6, p < .001], a EVG-based ARV (vs. DTG, aHR 1.3 95% CI: 1.1-1.7, p = .049), and a peak HIV-RNA >500k cp/mL (aHR 1.3, 95% CI: 1.1-1.6, p = .006) predicted INI discontinuation. Our data confirm the good tolerability of INIs in clinical practice. Differences emerge between the three drugs in reasons for discontinuation.
- Published
- 2021
- Full Text
- View/download PDF
15. Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
- Author
-
Capetti AF, Atzori C, Cossu MV, Ciccullo A, Restelli S, Piscaglia M, Gallazzi I, Meraviglia P, DiGiambenedetto S, and Rizzardini G
- Published
- 2019
- Full Text
- View/download PDF
16. An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
- Author
-
Giacomet V, Cossu MV, Capetti AF, Zuccotti G, and Rizzardini G
- Subjects
- Adenine administration & dosage, Adenine analogs & derivatives, Adolescent, Alanine, Child, Cobicistat administration & dosage, Emtricitabine administration & dosage, Humans, Quinolones administration & dosage, Tablets, Tenofovir analogs & derivatives, United States, United States Food and Drug Administration, Anti-HIV Agents administration & dosage, HIV Infections drug therapy
- Abstract
Introduction: Approximately 2.1 million of the estimated 36 million infected with HIV are children or adolescents. International guidelines for HIV-1 Infection suggest starting antiretrovirals (ARV) at the moment of diagnosis. Many factors limit the optimization of antiretroviral therapy in children and adolescents: lack of pediatric formulations, poor adherence, metabolic and pharmacokinetic changes associated withnormal child development and puberty. Areas covered: Three integrase inhibitors are approved by the US Food and Drug Administration and by European Medical Agency for children and adolescents with HIV-1 infection. Raltegravir is approved for children aged 4 weeks to 18 years, while dolutegravir and elvitegravir co-formulated with cobicistat, emtricitabine, and tenofovir alafenamide (E/C/FTC/TAF) are approved for children from 6 years of age. This article evaluates E/C/FTC/TAF as a treatment option. Expert opinion: E/C/FTC/TAF was well tolerated, and the antiretroviral activity and tolerability data of this combination support the use in children and adolescents. However, the studies regarding E/C/FTC/TAF in children and adolescents are scant. Consequently, additional studies investigating its safety and efficacy in children are paramount.
- Published
- 2019
- Full Text
- View/download PDF
17. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
- Author
-
Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, Baldin GM, Soria A, Riccardi N, Niero FP, Celesia BM, Barbarini G, Rusconi S, and Rizzardini G
- Subjects
- Adult, Aged, Cohort Studies, Female, HIV Infections virology, Humans, Italy, Male, Middle Aged, Oxazines, Piperazines, Pyridones, Reproducibility of Results, Salvage Therapy, Darunavir therapeutic use, HIV Infections drug therapy, HIV Integrase Inhibitors therapeutic use, HIV Protease Inhibitors therapeutic use, HIV-1 drug effects, Heterocyclic Compounds, 3-Ring therapeutic use
- Abstract
Background: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance., Objective: Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens., Methods: All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks., Results: The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1-5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1-49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides., Conclusions: These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.
- Published
- 2018
- Full Text
- View/download PDF
18. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
- Author
-
Capetti AF, Cossu MV, Sterrantino G, Barbarini G, Di Giambenedetto S, De Socio GV, Orofino G, Di Biagio A, Celesia BM, Rusconi S, Argenteri B, and Rizzardini G
- Subjects
- Adult, Cholesterol, HDL blood, Cholesterol, LDL blood, Drug Substitution, Drug Therapy, Combination, Female, HIV Infections blood, HIV Infections virology, HIV-1 genetics, Humans, Male, Middle Aged, Oxazines, Piperazines, Pyridones, RNA, Viral analysis, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Rilpivirine therapeutic use
- Abstract
Background: Data from clinical studies confirm the efficacy of switching to dolutegravir (DTG) plus rilpivirine (RPV) in selected patients., Objective: The primary objective is to report the 96-week virological suppression in our cohort, assessing the durability of this strategy in complicated situations. The secondary objective is to describe the safety and metabolic profile., Methods: All patients who had switched to DTG plus RPV between October 1, 2014, and September 30, 2015, were analyzed using a retrospective-prospective design, approved by ethics committees. Routine metabolic, immunological, and virological data were regularly sent to the coordinating center. Viral control was classified as HIV-1 RNA ≥50 copies/mL, 1 to 49 copies/mL, or undetectable (no virus detected [NVD])., Results: We followed 145 patients for a median of 101 weeks. The median age was 52 years; 31.7% were women, and 9.6% non-Caucasian; 50.3% had failed at least 1 antiretroviral regimen; and 15% had ≥50 copies/mL at baseline. The reasons for switching were as follows: simplification (51.7%), toxicity (36.5%), drug-drug interactions (6.9%), persistent low-level viremia (3.0%), nonadherence (2.1%), and viral failure (1.4%). By week 96, seven patients dropped out. At week 96, none had ≥50 HIV-1 RNA copies/mL, 138 (95.2%) had <50 copies/mL, and 123 (84.8%) had NVD. The low- to high-density lipoprotein cholesterol (LDL-C/HDL-C) ratio decreased significantly ( P = 0.04). Of the 287 baseline altered laboratory parameters, 32.7% normalized by week 96. Serum glucose and total- and LDL-cholesterol normalization were statistically significant., Conclusions: Switching to DTG plus RPV improved viral suppression and LDL-C/HDL-C ratio.
- Published
- 2018
- Full Text
- View/download PDF
19. Does simplification to dolutegravir-based dual regimens impact on the CD4+/CD8+ T-cell ratio?
- Author
-
Capetti AF, Orofino G, Paladini L, Sterrantino G, DiGiambenedetto S, De Socio GV, Cenderello G, Cossu MV, and Rizzardini G
- Subjects
- Humans, Oxazines, Piperazines, Pyridones, Treatment Outcome, Anti-HIV Agents administration & dosage, Antiretroviral Therapy, Highly Active methods, CD4-CD8 Ratio, Heterocyclic Compounds, 3-Ring administration & dosage
- Published
- 2018
- Full Text
- View/download PDF
20. Morning dosing for dolutegravir-related insomnia and sleep disorders.
- Author
-
Capetti AF, Di Giambenedetto S, Latini A, Sterrantino G, De Benedetto I, Cossu MV, and Gori A
- Subjects
- Female, Heterocyclic Compounds, 3-Ring, Humans, Oxazines, Piperazines, Pyridones, HIV Infections, Sleep Initiation and Maintenance Disorders
- Published
- 2018
- Full Text
- View/download PDF
21. Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.
- Author
-
Capetti AF, Cossu MV, Paladini L, and Rizzardini G
- Subjects
- Anti-HIV Agents administration & dosage, Anti-HIV Agents therapeutic use, Drug Therapy, Combination, HIV-1 drug effects, Humans, Oxazines, Piperazines, Pyridones, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring administration & dosage, Rilpivirine administration & dosage
- Abstract
Introduction: The HIV-infected population is aging and comorbidities and polypharmacological regimens are increasing. To reduce toxicity and drug burden researchers are evaluating the efficacy, safety and durability of dual therapies as a switch option in subjects who have achieved stable virologic suppression. Initially effective dual combinations relied on protease inhibitors but when dolutegravir, the first integrase inhibitor to display a high genetic barrier, became commercially available, many physicians began to use it in a variety of dual regimens, generating several observational cohorts. Areas covered: This review covers the most recent data from observational cohorts and randomized clinical trials concerning the switch to the dual combination of dolutegravir plus rilpivirine and the reasons that lead to consider this option. Also, viral failures, due to poor adherence or to other factors, and drug resistance are investigated. Articles which are searchable on MEDLINE/PubMed and from the main national/international congresses in the field of HIV therapy are reviewed. Expert opinion: The observation period for this regimen is getting longer and data showing its efficacy in maintaining HIV-1 RNA < 50 copies/mL are now consolidated. Metabolic data suggest some benefit in the lipid profile, improvement in bone mineral density and reduced bone reabsorption.
- Published
- 2018
- Full Text
- View/download PDF
22. Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.
- Author
-
Capetti AF, Astuti N, Cattaneo D, and Rizzardini G
- Subjects
- Animals, Anti-HIV Agents adverse effects, Anti-HIV Agents pharmacokinetics, Drug Interactions, Drug Therapy, Combination, HIV-1 drug effects, Heterocyclic Compounds, 3-Ring adverse effects, Heterocyclic Compounds, 3-Ring pharmacokinetics, Humans, Oxazines, Piperazines, Pyridones, Randomized Controlled Trials as Topic, Rilpivirine adverse effects, Rilpivirine pharmacokinetics, Anti-HIV Agents administration & dosage, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring administration & dosage, Rilpivirine administration & dosage
- Abstract
Introduction: The search for simple, potent, metabolic-friendly and nucleoside/nucleotide sparing antiretroviral regimens has led clinical investigators to move steps towards dual therapies. Among these the association of rilpivirine and dolutegravir is emerging as a twin randomized clinical trial (SWORD1&2) and at least three observational cohort describe it as a safe and highly effective regimen for switch from other therapies Areas covered: We review the evidence supporting the use of dolutegravir plus rilpivirine for the treatment of HIV in virologically suppressed patients taking other antiretroviral regimens. The reasons for the switch in clinical practice may range from simplification to tolerability/toxicity issues, to the prevention of future metabolic damage, to predicted drug-drug interactions when treatment of HCV co-infection is planned. Articles searchable on MEDLINE/PubMed and from the main international congresses in the field of HIV therapy were reviewed to provide context for use of dolutegravir plus rilpivirine Expert opinion: This treatment is highly effective in maintaining HIV-1 RNA <50 copies/mL. Although the studies up to date requested patient to switch to drugs they had no experience of, a predictable 'radical change' effect did not impact negatively on the results. Further data from these studies may help elucidate the possible advantage in terms of safety and metabolic effect in the next few months.
- Published
- 2017
- Full Text
- View/download PDF
23. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
- Author
-
Capetti AF, Cossu MV, Orofino G, Sterrantino G, Cenderello G, De Socio GV, Cattelan AM, Soria A, Rusconi S, Riccardi N, Baldin GM, Niero FP, Barbarini G, and Rizzardini G
- Subjects
- Drug Resistance, Viral, Drug Therapy, Combination, Female, HIV Infections virology, HIV-1 drug effects, HIV-1 genetics, Humans, Lost to Follow-Up, Male, Middle Aged, Oxazines, Piperazines, Pyridones, Treatment Outcome, Viral Load, Anti-HIV Agents therapeutic use, Darunavir therapeutic use, HIV Infections drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Ritonavir therapeutic use
- Abstract
Background: Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy., Methods: All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight Italian centres were included in the analysis. The main metabolic data, efficacy parameters and safety data routinely collected were provided. This observational study is aimed to assess the efficacy of such approach. The primary end-point was the proportion of subjects achieving or maintaining virologic suppression <50 copies/mL at week 24. Secondary end points were maintaining virologic suppression in the follow-up (weeks 48 and 96) and safety., Results: One hundred and thirty subjects were followed for a median of 56 months. Reasons for switching were simplification (44.6%), viral failure (30%), toxicity (16.9%), non-adherence (4.6%), persistent low-level viremia (3.1%), and drug-drug interaction (0.8%). At baseline, 118 subjects had documented resistance to 1 to 5 antiretroviral classes while 12 had viral rebound at a time when genotypic tests were not yet available. Seventeen and 14 subjects took DRV/r and DTG twice daily, respectively. One subject was lost to follow-up, one discontinued for liver enzymes' elevation, one died of illicit drug abuse and one of cancer-related complications. The proportion of subjects with ongoing HIV replication dropped from 40% to 6.1%. Those with undetectable viral load increased from 38.5% to 76.2%. At week 48, 17.7% had HIV RNA between 1 and 49 copies/mL. The number of subjects with altered serum glucose, creatinine, ALT, AST, total-, HDL- and LDL-cholesterol, triglycerides and MDRD <90 mL/min decreased by week 48, while those having MDRD <60 mL/min remained 4.6%. Overall 90/283 baseline laboratory alterations returned to normality., Conclusions: Switching to DTG plus DRV/r proved to be safe, suppressing viral replication without metabolic impact.
- Published
- 2017
- Full Text
- View/download PDF
24. Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.
- Author
-
Capetti AF, Micale M, Carenzi L, Niero F, Landonio S, Vimercati S, Dedivitiis G, and Rizzardini G
- Subjects
- Adult, Drug Therapy, Combination, Female, Humans, Male, Maraviroc, Medication Adherence, Middle Aged, Retrospective Studies, Young Adult, Cyclohexanes therapeutic use, HIV Fusion Inhibitors therapeutic use, HIV Infections drug therapy, Protease Inhibitors therapeutic use, Triazoles therapeutic use
- Abstract
In view of the forthcoming long-acting antiretrovirals, measures should be taken to prevent the selection of HIV drug resistance mutations. All subjects who had been switched to boosted protease inhibitors plus maraviroc (bPIs/MVC) with baseline HIV-1 RNA >50 copies/mL between June, 2014, and April, 2015, were retrospectively evaluated. HIV-1 RNA, CD4+ T-cells, serum glucose, creatinine, ALT, and adverse events were controlled every 3 to 4 months. We retrospectively analyzed 44 patients: 18 were taking darunavir/ritonavir (DRV/r) and 26 atazanavir/ritonavir (ATV/r) once daily, plus MVC 300 mg once daily. Seven subjects were in CDC stage C. All had a follow-up of at least 24 weeks, 28 exceeded 48 weeks, and 21 exceeded 72 weeks. All had experienced at least 1 viral failure and had selected at least 1 resistance-associated mutation (RAM). At baseline, 38 had plasma HIV-1 RNA 50-499 copies/mL and 6 had ≥500. At week 24, none had viremia >500 and 30 (68.2%) had suppressed HIV-1 RNA below 50 copies/mL. Of the subgroup with 48 weeks' follow-up, 23 had HIV-1 RNA 50-499 copies/mL, 5 had ≥500, and 20/28 suppressed to <50 copies/mL. Of the longest observed subgroup (72 weeks), 17 had HIV-1 RNA 50-499 copies/mL, and 4 had ≥500 copies/mL and 15/21 (71.4%) suppressed to <50 copies/mL. This combination allowed fair suppression of viral replication, with minor genotypic evolution in 6 subjects, and seems to be a feasible strategy to prevent damaging future options.
- Published
- 2017
- Full Text
- View/download PDF
25. Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
- Author
-
Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, and Sasset L
- Subjects
- Adult, Aged, Aged, 80 and over, Antiretroviral Therapy, Highly Active, Cohort Studies, Drug Resistance, Viral, Drug Substitution, Female, HIV-1 genetics, Humans, Italy, Male, Middle Aged, Mutation, Oxazines, Piperazines, Pyridones, RNA, Viral, Retreatment, Salvage Therapy, Viral Load, Virus Replication drug effects, Young Adult, Darunavir therapeutic use, HIV Infections drug therapy, HIV Infections virology, HIV-1 drug effects, Heterocyclic Compounds, 3-Ring therapeutic use, Ritonavir therapeutic use
- Abstract
Background: Dolutegravir plus darunavir provide a high genetic barrier to HIV-1 resistance and are suitable for simple salvage regimens., Methods: All HIV-1-infected subjects treated with dolutegravir plus boosted darunavir dual therapy between March 2011 and September 2015 were included in an observational cohort. Data were collected at baseline and at weeks 4, 12, 24 and 48., Results: We enrolled 113 subjects. After week 24, one was lost at follow-up, one dropped out for grade 2 elevation of liver enzymes, one died from illicit drug abuse and one from cancer-related sepsis. The mean age was 51, 26.5% were female and 9.7% were non-Caucasian. Twenty had never experienced failure. A total of 99 had reverse-transcriptase (RT) mutations, 87 had protease inhibitor mutations and 12 had integrase strand transfer inhibitor (INSTI) mutations. Viraemic patients declined from baseline to week 24 from 43.4% to 6.2%, the remainder being due to high baseline viraemia or adherence issues. The proportion of subjects with viraemia 1-49 copies/ml remained at 20.4% while those in whom no virus was detected (NVD) increased from 36.3% to 73.5% by week 24. All the 47 subjects who had a 48-week follow-up had <50 copies/ml and 42 (89.4%) had NVD. 18 subjects had reduced sensitivity to darunavir (Stanford median score 15, range 15-40), but none rebounded, 6 having a 24-week and 7 a 48-week follow-up. The median variation in serum creatinine was -0.01 (range +0.2 to -0.21) mg/dl., Conclusions: This dual regimen provides a simple salvage regimen and proved safe and effective in this cohort.
- Published
- 2017
- Full Text
- View/download PDF
26. Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
- Author
-
Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, Rusconi S, Riccardi N, Baldin GM, Cima S, Niero FP, Rizzardini G, and Sasset L
- Published
- 2017
- Full Text
- View/download PDF
27. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
- Author
-
Capetti AF, Sterrantino G, Cossu MV, Orofino G, Barbarini G, De Socio GV, Di Giambenedetto S, Di Biagio A, Celesia BM, Argenteri B, and Rizzardini G
- Subjects
- Adult, Aged, Antiretroviral Therapy, Highly Active, Cohort Studies, Creatinine blood, Drug Administration Schedule, Drug Interactions, Drug Resistance, Viral, Drug Therapy, Combination, Female, Follow-Up Studies, HIV Infections virology, HIV Integrase Inhibitors adverse effects, HIV-1 genetics, HIV-1 isolation & purification, Headache etiology, Heterocyclic Compounds, 3-Ring adverse effects, Humans, Male, Middle Aged, Oxazines, Piperazines, Pyridones, RNA, Viral blood, Reverse Transcriptase Inhibitors adverse effects, Rilpivirine adverse effects, Sleep Initiation and Maintenance Disorders etiology, HIV Infections drug therapy, HIV Integrase Inhibitors therapeutic use, Heterocyclic Compounds, 3-Ring therapeutic use, Reverse Transcriptase Inhibitors therapeutic use, Rilpivirine therapeutic use
- Abstract
Introduction: Little information is available on the efficacy and safety of the dual combination of ripivirine plus dolutegravir. This work aims at beginning to fill this gap., Methods: All HIV-1 infected subjects treated with ripivirine plus dolutegravir between October 2014 and September 2015 in eight Italian centres were included in an observational cohort. Data were collected at baseline and at weeks 4, 12, 24 and 48., Results: One hundred and thirty-two subjects were followed for a median of 24 months, mean 33 months. One subject discontinued the study drug at week 24 for headache, one for drug interaction and one died after week 24 of illicit drug abuse. The mean age was 51.8, females 31.7% and non-caucasians 10%. Fifty-seven (43.2%) had at least one failure in their treatment history. Reasons for switching were simplification (53.0%), toxicity (34.8%), drug interactions (n = 7), persistent low-level viremia (n = 4), non-adherence (n = 3) and viral failure (n = 2). Sixty patients (45.5%) had reverse transcriptase (RT) mutations and 69 (44,7%) had protease (PR) mutations. Sixteen had baseline viral replication, 27 had < 50 HIV-1 RNA copies/mL and in 89 (67.4%) no virus was detected (NVD, 0 copies/mL). At w4, 114 (86.4%) had NVD, 15 had 1 to 49 HIV-1 RNA copies/mL and 3 had 50 to 57 copies/mL. At week 24 one subject had viral rebound without mutations due to missed drug refill, 19 had 1 to 49 copies/mL, and 112 had NVD. All 132 subjects were tested at weeks 4 and 24. Of the 50 subjects who had a 48-week follow-up, one had a treatment interruption, four had 1 to 49 copies/mL and 45 had NVD. Among the entire population, one subject had low-level, one intermediate and 4 high-level resistance to rilpivirine: none failed by week 48. Mean serum creatinine increased by +0.1 mg/dL. During the follow-up one patient reported headache and insomnia., Conclusions: Ripivirine plus dolutegravir proved safe and effective in this cohort of non-naïve HIV-1 infected subjects., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2016
- Full Text
- View/download PDF
28. Anti-inflammatory effect of maraviroc in an HIV-infected patient with concomitant myositis: a case report.
- Author
-
Capetti AF, Pocaterra D, Zucchi P, Carenzi L, and Rizzardini G
- Subjects
- Aged, Anti-Inflammatory Agents administration & dosage, Antiretroviral Therapy, Highly Active, Chronic Disease, Creatine Kinase blood, Cyclohexanes administration & dosage, HIV Fusion Inhibitors administration & dosage, HIV Infections drug therapy, HIV Infections virology, Humans, Male, Maraviroc, Treatment Outcome, Triazoles administration & dosage, Anti-Inflammatory Agents therapeutic use, Cyclohexanes therapeutic use, HIV Fusion Inhibitors therapeutic use, HIV Infections complications, Myositis complications, Myositis drug therapy, Triazoles therapeutic use
- Abstract
We report the surprising yet sought impact that an antiretroviral (ARV) regimen containing maraviroc had on an HIV-infected and heavily highly active antiretroviral therapy (HAART)-experienced patient with chronic polymyositis. The patient had elevated creatine kinase (CK) levels in serum for 6 years, reaching peaks over 900 U/L and showing only partial response to high-dose steroids, not responding to HAART withdrawal. The disease started while on second-line HAART and gradually impaired his muscular function, leading to the absolute loss of the ability to stand on his legs. Atherosclerosis and hypertension contributed to the development of myocardial infarction. The association of unboosted atazanavir (ATV) plus maraviroc was designed hoping in a protective role on the cardiovascular system and in an anti-inflammatory effect that some authors have hypothesized. After only 3 months the patient's CK levels had normalized and with the help of rehabilitation he recovered the ability to walk, which he still maintains at the one year of observation.
- Published
- 2010
- Full Text
- View/download PDF
29. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
- Author
-
Capetti AF, Piconi S, Landonio S, Rizzardini G, and Perno CF
- Subjects
- Adult, Aged, Darunavir, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Raltegravir Potassium, Treatment Outcome, HIV Infections drug therapy, HIV Integrase Inhibitors therapeutic use, HIV Protease Inhibitors therapeutic use, Pyrrolidinones therapeutic use, Salvage Therapy, Sulfonamides therapeutic use
- Published
- 2009
- Full Text
- View/download PDF
30. Can a K103N HIV strain stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure?
- Author
-
Capetti AF, Gabris AI, Drago L, and Vigevani GM
- Subjects
- Drug Resistance, Viral, Female, HIV Infections drug therapy, Humans, Middle Aged, Selection, Genetic, Anti-HIV Agents therapeutic use, HIV Infections genetics, HIV-1 genetics, Mutation genetics, Reverse Transcriptase Inhibitors therapeutic use
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.